Homecoming

Homecoming is a health‑technology company that builds a purpose‑built electronic health record (EHR) and patient engagement platform for psychedelic therapy clinics and retreats, helping clinicians manage intake, preparation, dosing journeys, integration and outcomes tracking in one HIPAA‑compliant workflow[2][1].

High‑Level Overview

• Concise summary: Homecoming is a clinician‑facing EHR and patient companion platform focused on psychedelic‑assisted care; it replaces ad hoc tools (Google Forms, Signal threads, Dropbox) with a single workflow for intake, booking, prep/integration programs, progress tracking and outcomes data collection[2][4].
  - Product / Who it serves / Problem solved / Growth momentum: Homecoming builds a simple EHR and patient engagement app designed for psychedelic clinics, therapists and retreat centers to streamline operations, improve patient adherence and capture outcomes and research‑grade data; that reduces administrative friction and improves continuity of care across preparation, dosing and integration phases[2][1]. The company raised an oversubscribed seed round (reported ~$4M) to scale the platform and expand clinic partnerships, and publicly positions itself as an early category leader in psychedelic therapy technology[1][4].

Origin Story

• Founding and background: Homecoming was launched by Yuriy Blokhin (founder & CEO) around 2021–2022 with an explicit mission to support high‑integrity psychedelic care and to amplify clinic capacity while giving back equity to psychedelic‑focused nonprofits; the company publicly announced a seed raise in April 2022[1][4].
  - How the idea emerged / early traction: The product grew from clinicians’ needs to replace fragmented communication and administrative tools with a single secure workflow tailored to psychedelic practice; early traction includes clinic and retreat pilot partnerships, advisor support from psychedelic‑medicine and tech veterans, and seed funding to scale the platform[4][1].

Core Differentiators

• Product differentiators: Purpose‑built EHR and workflows specifically for psychedelic care (intake, prep, integration, outcomes and referrals) rather than a generic therapy EHR[2].
  - Developer / user experience: Claims an intuitively designed client portal and forms that improve completion rates and clinician visibility into client progress[2].
  - Operational impact: Consolidates booking, CRM, program delivery and outcomes export for research and compliance, reducing the administrative overhead of clinics[2][1].
  - Community / mission alignment: Public commitment of equity to nonprofit psychedelic organizations and advisory board drawn from both psychedelic research and consumer‑tech backgrounds, signaling alignment with clinical and research communities[1][4].

Role in the Broader Tech Landscape

• Trend they’re riding: Increasing clinical and research interest in psychedelic‑assisted therapies for mental health has created demand for specialized digital tooling to scale safe, standardized care and outcomes measurement[1][4].
  - Why timing matters: As clinics move from informal, ad hoc tooling toward regulated, evidence‑driven care, there’s an opening for verticalized EHRs that capture preparation/integration workflows and outcomes data needed for research and reimbursement[2][1].
  - Market forces in their favor: Growing investment into psychedelic medicine, expanding clinic networks and the need for HIPAA‑compliant, research‑ready data capture all support adoption of dedicated platforms[1][2].
  - Influence on ecosystem: By standardizing workflows and enabling outcomes collection, Homecoming can accelerate clinic scalability, improve data availability for clinical studies, and reduce operational barriers for therapists entering the field[2][1].

Quick Take & Future Outlook

• What’s next: Expect Homecoming to continue scaling clinic partnerships, deepen features for outcomes tracking and research exports, and expand integrations (EMR/workflow, payment, scheduling) to entrench itself as a category EHR for psychedelic care[1][2].
  - Shaping trends: Regulatory clarity, clinical trial outcomes for psychedelic treatments, and payer/reimbursement developments will determine how broadly such platforms are adopted; success in aggregating high‑quality outcomes data would make Homecoming more strategic to both clinics and researchers[1][2].
  - How influence might evolve: If Homecoming sustains product‑market fit and grows a sizable clinic network plus research partnerships, it could become the de facto operational layer for scaled, standardized psychedelic therapy—shifting the field from trial‑level pilots to routine clinical programs[2][1].

Quick factual notes: Homecoming publicly markets itself as a simple EHR for psychedelic care and announced a ~$4M seed financing in 2022; its core positioning and features are described on its product site and in press coverage[2][1].